Intimation of Closure of Trading Window for the Quarter ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma has informed the stock exchange that its trading window will be closed from 1st October 2025 until 48 hours after the conclusion of the upcoming Board Meeting. The Board Meeting is being held to consider and approve the Un-Audited Financial Results for the quarter and half-year ended 30th September 2025 (Q2 FY26). During this closed window, designated persons of the company are prohibited from trading in the company's shares. The exact date of the Board Meeting will be communicated separately. The intimation was signed by Director Ms. Chaitali Kalpataru Shah on 27th September 2025.
This is a routine compliance filing under SEBI Insider Trading Regulations and signals that Q2 FY26 results are likely to be announced in early October. It does not directly affect shareholders but indicates an upcoming earnings announcement, which may trigger short-term stock movement depending on the results.